TERUMO CORPORATION


3rd Quarter Financial Results for FYE/Mar.2008




Sales and Profits Enjoyed Double-digit Growth


	Q3 FYE/Mar. 2007	Q3 FYE/Mar. 2008	Rate of change
Net Sales	205.1	231.4	13%
Gross Profit (%)	113.2 (55.2%)	127.5 (55.1%)	13%
S.G.A Expenses (%)	68.0(33.2%)	75.1(32.4%)	10%
Operating Income (%)	45.2(22.0%)	52.4(22.7%)	16%
Ordinary Income (%)	46.3(22.5%)	52.9(22.9%)	14%
Net Income (%)	29.5	34.8	18%
	US\$ 116 yen EUR 148 yen	117 yen 163 yen	






Financial Summary








Net Sales (by Product Group)






S.G.A expenses

(Unit : Billion yen)

% in

change



	2001	2000			
ersonnel	23.6	26.6	+2.9	12.4%	
gistics	5.7	6.8	+1.1	18.7%	
ales promotion d advertising	6.9	7.6	+0.7	9.7%	
&D	11.6	11.8	+0.2	1.4%	
hers	20.1	22.4	+2.3	11.2%	
otal	68.0	75.1	+7.1	10.4%	

Q3

2008

FYE/Mar. FYE/Mar. Change

Q3

2007





FYE / March 2008 Forecast

	FYE/Mar. 2007	FYE/Mar. 2008	Rate of change
Net Sales	276.4	305.0	10%
Operating Income (%)	58.5(21.2%)	65.0(21.3%)	11%
Ordinary Income (%)	58.0(21.0%)	65.0(21.3%)	12%
Net Income	37.2	42.0	13%

Average	US\$	117 yen	113 yen
Exchange rate	EUR	150 yen	159 yen




Topics


Growth strategy for Domestic general hospital products




Growth trend seen in a harsh domestic market





General hospital products contribute the current growth











Terumo Medical Pranex

Training for medical professionals

About 8,000 medical professionals have visited the site since the renewal open of April 2007







DES, "Nobori" acquired CE mark

• Europe

- Sales will start in 4Q
- Clinical tests planned after commercialization

Japan

- Clinical tests in progress

• Asia

- Sales have already started





Winning No.1 share in the domestic market!

Contributing to medical economic improvement
Supports a variety of needs with a single unit,

completing treatment with a small number of catheters

Highly pressure-resistant


Expands hard, calcificated blood-vessels with high pressure Maintains high passage capability

Reaches thinner bloodvessels after expansion



The next mid-term plan will be announced on April 30





IR Contact

TERUMO Corporation

Corporate Communication (IR) Dept.

E-mail: CCD@terumo.co.jp

This document contains forward-looking statements that reflect management's current views with respect to certain future events and financial performance. Actual results may differ materially from those projected or implied in the forward-looking statements and from historical trends. Furthermore, certain forward-looking statements are based upon assumptions of future events that may not prove to be accurate. Factors that could cause actual results to differ materially from those projected or implied in any forward-looking statements include, but are not limited to, changes in overall economic conditions, fluctuations of foreign exchange rates, and intensifying price competition in the markets for our products.

